Edition:
United States

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

28.94USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$28.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,429
52-wk High
$30.11
52-wk Low
$7.35

Latest Key Developments (Source: Significant Developments)

Acer Therapeutics Reports Q2 Loss Per Share Of $0.64
Monday, 13 Aug 2018 04:01pm EDT 

Aug 13 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.64.Q2 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.ACER THERAPEUTICS-BELIEVE CASH POSITION, WITH PROCEEDS FROM AUG OFFERING, TO BE SUFFICIENT TO FUND CURRENT OPERATING AND CAPITAL REQUIREMENTS H1 2020.ACER THERAPEUTICS - CASH POSITION. CASH AND CASH EQUIVALENTS WERE $8.3 MILLION AS OF JUNE 30, VERSUS $15.6 MILLION AS OF DEC 31, 2017.  Full Article

Acer Therapeutics Q4 Loss Per Share $0.63
Wednesday, 7 Mar 2018 04:01pm EST 

March 7 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.63.  Full Article

Acer Therapeutics Announces Closing Of Underwritten Public Offering Of Common Stock
Thursday, 14 Dec 2017 04:01pm EST 

Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.  Full Article

Acer Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
Tuesday, 12 Dec 2017 09:00am EST 

Dec 12 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - ANNOUNCED PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 916,667 SHARES OF COMMON STOCK AT $12.00/SHARE.  Full Article

Acer Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock
Monday, 11 Dec 2017 04:01pm EST 

Dec 11 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT EFFORTS, TO SEEK REGULATORY APPROVAL FOR EDSIVO.ACER THERAPEUTICS INC - ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO INVEST IN PRE-COMMERCIAL ACTIVITIES FOR EDSIVO, AMONG OTHERS.  Full Article

Acer Therapeutics Q3 loss per share $1.09
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Acer Therapeutics Inc ::Acer Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.09.  Full Article

Acer Therapeutics raises $15.7 million in Equity Financing
Wednesday, 4 Oct 2017 02:05pm EDT 

Oct 4 (Reuters) - Acer Therapeutics Inc :Files to say that it has raised $15.7 million in Equity financing-SEC filing‍​.  Full Article

Acer Therapeutics reports positive results from clinical trial of medicine for connective tissue disorder
Monday, 25 Sep 2017 08:30am EDT 

Sept 25 (Reuters) - Acer Therapeutics Inc ::Acer Therapeutics reports positive results from pivotal clinical trial of edsivo™ (celiprolol) for treatment of vascular ehlers-danlos syndrome.Acer Therapeutics Inc - ‍company intends to file NDA for edsivo™ in first half of 2018​.Acer Therapeutics Inc - retrospective source verified analysis of trial data confirmed data from previously published clinical study of celiprolol​.  Full Article

Opexa Therapeutics reports qtrly loss per share $0.09
Monday, 14 Aug 2017 08:08am EDT 

Aug 14 (Reuters) - Opexa Therapeutics Inc :Qtrly loss per share $0.09.  Full Article

Opexa therapeutics Inc says subsidiary Opexa Merger Sub to merge with Acer Therapeutics
Monday, 3 Jul 2017 06:44am EDT 

July 3 (Reuters) - Opexa Therapeutics Inc :Opexa Therapeutics Inc - on june 30, co, Opexa Merger Sub , and acer therapeutics entered into an agreement and plan of merger and reorganization.Opexa Therapeutics Inc - co's subsidiary Opexa Merger Sub to merge with and into Acer Therapeutics, with Acer becoming wholly-owned subsidiary of co.Opexa Therapeutics -at closing of deal, each outstanding share of Acer stock to be converted to right to receive about one share of stock of co.Opexa Therapeutics - following merger, co shareholders expected to own approximately 11.2% of the combined company.Opexa-After deal,current Acer shareholders expected to own about 63.8% of combined co,investors participating in financing expected to own about 25%.Opexa Therapeutics Inc - deal for approximately $15.7 million.  Full Article

BRIEF-Acer Therapeutics Q4 Loss Per Share $0.63

* ACER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE